All In Biotech

Drug Trial Radar · NCT04906460

Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)

An Open-label Phase 1b/2 Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy

Last checked: Nov 20, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

25

Actual

Start

Sep 28, 2021

Primary completion

Oct 2026

Study completion Apr 24, 2027

Sponsor

Lead sponsor
Wave Life Sciences USA, Inc.Industry
Sponsor type
Industry
First posted
May 28, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 4 years, up to 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1b/2 open-label study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and clinical effects of intravenous (IV) WVE-N531 in patients with Duchenne muscular dystrophy (DMD). To participate in the study, patients must have a documented mutation of the DMD gene that is amenable to exon 53 skipping intervention. This study has 3 parts, Part A, Part B, including Part B Extension Arm, and Part C. Part A is completed. Part B is completed. Following completion of Part B, all patients elected to continue to receive study drug in the optional Part B open-label Extension Arm. Part C has been added to the study and will enroll new patients.

Conditions

  • Duchenne Muscular Dystrophy

Interventions

  • WVE-N531Drug

    WVE-N531 is an antisense oligonucleotide (ASO)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A: Safety: Proportion of patients with adverse events (AEs)Time frame: Day 1 (initial dose) up to 24 weeks after the last dose of Part A
  2. Part B: Pharmacodynamics: Dystrophin level (% normal dystrophin) as assessed by Western blot of muscle tissue following multiple doses of WVE-N531Time frame: At Week 26 and at Week 50 of Part B
  3. Part C: Pharmacodynamics: Change from baseline dystrophin level (% normal dystrophin) as assessed by a validated assay analysis in muscle tissue following multiple doses of WVE-N531Time frame: At Baseline and following 24 weeks of treatment in Part C

Locations

6 sites in 3 countries. Site status is shown where the registry gives one.

  • Arkansas Children's Hospital

    Little Rock, Arkansas

  • Rare Disease Research LLC

    Atlanta, Georgia

  • Istiklal Hospital/ Clinical Research Unit

    Amman, Jordan

  • The Specialty Hospital (TSH)/ Advanced Clinical Center

    Amman, Jordan

  • King Abdullah University Hospital (KAUH)

    Irbid, Jordan

  • Oxford Children's Hospital, Oxford University Hospitals NHS Foundation Trust

    Headington, Oxford, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.